SR One and Roche Venture Fund-backed Pandion Therapeutics will use the proceeds from the offering to advance a lead drug candidate for ulcerative colitis.

Pandion Therapeutics, a US-based autoimmune disease drug developer backed by conglomerate Access Industries and pharmaceutical firms Roche and GlaxoSmithKline (GSK), has filed for a $75m initial public offering.

Founded in 2016, Pandion is utilising protein engineering to develop treatments for autoimmune diseases. Part of the proceeds from the IPO will support phase 1a and phase 1b/2a clinical trials for its lead product candidate, PT101, which targets ulcerative colitis.

Additional capital will be used to advance two autoimmune disease candidates,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn